J. Carmichael

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

K. Swenerton, J Jeffrey, Gavin Stuart et al. · Journal of Clinical Oncology · 1992 · 214 citations

Medicine, Gynecology, Oncology +17

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · Journal of Clinical Oncology · 2009 · 175 citations

Medicine, Oncology, Pharmacology +15

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · Journal of Clinical Oncology · 2009 · 121 citations

Medicine, Oncology, Pharmacology +15

Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer

M. William Audeh, R. T. Penson, Michael Friedländer et al. · Journal of Clinical Oncology · 2009 · 107 citations

Medicine, Oncology, Pharmacology +16

Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.

Wendy Shelley, A A Starreveld, M.E. Kirk et al. · Journal of Clinical Oncology · 1988 · 95 citations

Medicine, Oncology, Radiation Oncology +17